# FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class

> **Newsylist Open Intelligence Dossier** · First detected: 2026-11-15 16:29 UTC · Category: Business · Sources: 6 · Current Velocity: 18.37

## Intelligence Brief
"FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class" developed substantial multi-source reporting across the Business sector, tracked across 5 distinct newsrooms by Newsylist.


Key reporting was led by Endpoints News, Bloomberg.com, Yahoo Finance and Reuters. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xV?
Coverage spiked when 5 independent newsrooms published 5 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Financial Times | FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector | 2026-11-15 12:50 | [Source Link](https://news.google.com/rss/articles/CBMihAFBVV95cUxQSF81czliZUJkMnRRbzNpUENZS2NDTm5QNzd5UkI3Qk10R1hmcnIyNnJfQVY1SkJlZkJnc2RMUzhobDh5VTI4cUs2NjIwN3FPdVhHSV9taHRhaDBJWjlNZUFHLThTd01vZGZzVklhLVV4NlFOTlZZWjEzN2s4RW1peDF5N0w?oc=5) |
| Endpoints News | FDA rejects Summit, Akeso’s ivonescimab in narrow lung cancer setting | 2026-11-15 12:50 | [Source Link](https://news.google.com/rss/articles/CBMilgFBVV95cUxNaGJ6bF9CdnU4ajdVM1FBSThXN29RZG5sWkllOFlCeElqVy10SHJ5Mmk5Tjl3bU1qWjhKWFFNU3dfX1FVUlNDWnhwVnoxX0tTNUV1V2ZCTDJodUVzNV93ZmN3SGFmU2ppRDBheHNsMmpoREllNlZncEV0ZFBDSU9SZENXdjdYZ3BxSVE2dk9ldVJNVlhfeEE?oc=5) |
| Bloomberg.com | US FDA Rejects Summit’s China-Originated Lung Cancer Drug | 2026-11-15 12:50 | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxPelZQa1Q5Rk16X1ViWXNVRzZsX3YtOVU5R01FcThBUzlEME5HUHpMWnltbGFuTnEwaHdnOUpySllUUzczaF9SMGZGTVJuLVZ3U1Fvd2pNQ2c2YWhaMXVSWjdSWlJQQlVVZ2Q3Tm1OaEVXOGJUYV9qNWR1bnpTMkZkSXRpZEdjRG5fZDBGUEZHUUoyWVdldkxhX2FZbUZrMXFlWWtnUVBadkZVYXY2?oc=5) |
| Yahoo Finance | Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application | 2026-11-15 12:50 | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxQRmNodG9Ybmc4V3BqZTA0elNfemZia18zVE1wYnVPdnJHNzRZX2x4UEkyYk5NUzBKU19VUjF3enFYTzZnMWZUQ0FNSVJ0TGR4NzZfSkczWWxnbXRrVzl3bGQzaTJrQWhTQ1M0Q3ZrN21rSFM1Ny1qOXRyTEJlZG9IbmstTmd6S1YwTmRxQzlVMVJWdjJpbHVMUnQyMFFPTURGNzkzZGVDS3B3Nl9fQkxHVA?oc=5) |
| Reuters | US FDA declines to approve Summit lung cancer drug after trial misses key survival goal | 2026-11-15 12:50 | [Source Link](https://news.google.com/rss/articles/CBMizAFBVV95cUxPSkdFR0ppNThGcnFUbE1vVHBkWG5GQkFrQ3B5M2x0VFh4bDNRVFdXUm9LazNYYUI4WnpBdXpQQ0NpS2llVWFEcE1LTWpLRWVqdFp4eTRibUtROW16ZU5XeXRmc1RwaTZCbzV2UXlKcEhvaHpCNlJSeTFucnl4ZXZvUWVWbXl2MUtHY1hXUzJ3SEFCR3ZZUDY2VGFuTC1lek80UmRZTGlxRkItd2I4S1lrcnotSF8tVG5tTnJySnBoMlJ0NXJtcEo5bjROV1c?oc=5) |
| Fierce Pharma | FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class | 2026-11-15 12:50 | [Source Link](https://news.google.com/rss/articles/CBMimwFBVV95cUxPRUFJWnNTQ00yaXJYT21NN1BCMUdpM3BjbjdyUk9WOEFIcGx4U090RlVIbXp6OGVjTkFBREhGUnUtclFRU3d5OS1PVkVNQk9tZGVGSS1wZmNMamlleFBMalZUQzFrNXB5TGN5SzFMd3REcTZCcG5IQXpMMkFYc2lac0VEbnZ4V2NuSTZ4VVJrRnd6TkJfdUtJWmt6VQ?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-11-15/fda-rejects-summit-s-ivonescimab-derailing-us-arrival-of-much-hyped-pd-1xvegf*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*